Cargando…
The need for a strategic therapeutic approach: multiple sclerosis in check
Multiple sclerosis (MS) is the most common chronic autoimmune neurological disease. Its therapeutic management has drastically evolved in the recent years with the development of specific disease-modifying therapies (DMTs). Together with the established injectables, oral and intravenous alternatives...
Autores principales: | Inojosa, Hernan, Proschmann, Undine, Akgün, Katja, Ziemssen, Tjalf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777338/ https://www.ncbi.nlm.nih.gov/pubmed/35070250 http://dx.doi.org/10.1177/20406223211063032 |
Ejemplares similares
-
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021) -
Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021) -
No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020) -
Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication
por: Inojosa, Hernan, et al.
Publicado: (2023) -
Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
por: Fischer, Stefanie, et al.
Publicado: (2021)